Epidemiology and Predisposing Factors of Post-COVID Venous Thrombosis: A Concise Review

Giuseppe Lippi; Emmanuel J. Favaloro

doi:10.1055/s-0043-1770051

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2024; 50(02): 271-274
DOI: 10.1055/s-0043-1770051

Review Article

Epidemiology and Predisposing Factors of Post-COVID Venous Thrombosis: A Concise Review

Giuseppe Lippi

¹Section of Clinical Biochemistry and School of Medicine, University of Verona, Verona, Italy

,

Emmanuel J. Favaloro

²Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW Australia

³School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia

⁴Faculty of Science and Health, Charles Sturt University, Wagga Wagga, NSW, Australia

› Institutsangaben

Abstract

Long-coronavirus disease 2019 (COVID-19) represents a heterogeneous clinical syndrome characterized by a pathologic continuum of signs, symptoms, and also laboratory/radiologic abnormalities that may persist for a long time after recovering from an acute severe acute respiratory syndrome-coronavirus disease 2 infection. Among the various components of this postviral condition, the risk of venous thromboembolism in patients hospitalized for COVID-19 remains considerably higher after discharge, especially in older individuals, in men, in patients with longer hospital stays and more aggressive treatment (e.g., mechanical ventilation and/or intensive care), when thromboprophylaxis is not used, and in those with a persistent prothrombotic state. Patients who have these predisposing factors should be monitored more closely to intercept any thrombosis that may occur in a post-COVID time-related manner but may also benefit from extended thromboprophylaxis and/or antiplatelet therapy.

Keywords

COVID-19 - SARS-CoV-2 - venous thrombosis - deep vein thrombosis - pulmonary embolism

Volltext

Referenzen

References
1 Lippi G, Henry BM, Favresse J, Plebani M. Addressing standardized definitions of post-COVID and long-COVID. Clin Chem Lab Med 2023; 61 (08) 1361-1362
2 Mudgal SK, Gaur R, Rulaniya S. et al. Pooled prevalence of long COVID-19 symptoms at 12 months and above follow-up period: a systematic review and meta-analysis. Cureus 2023; 15 (03) e36325
3 Turner S, Khan MA, Putrino D, Woodcock A, Kell DB, Pretorius E. Long COVID: pathophysiological factors and abnormalities of coagulation. Trends Endocrinol Metab 2023; 34 (06) 321-344
4 Martins-Gonçalves R, Hottz ED, Bozza PT. Acute to post-acute COVID-19 thromboinflammation persistence: mechanisms and potential consequences. Curr Res Immunol 2023; 4: 100058
5 Zanini G, Selleri V, Roncati L. et al. Vascular “long COVID”: a new vessel disease?. Angiology 2024; 75 (01) 8-14
6 Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost 2020; 46 (07) 763-771
7 Lippi G, Favaloro EJ. What we know (and do not know) regarding the pathogenesis of pulmonary thrombosis in COVID-19. Semin Thromb Hemost 2023; 49 (01) 27-33
8 Zuin M, Engelen MM, Barco S. et al. Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: a systematic review and meta-analysis. Thromb Res 2022; 209: 94-98
9 Mansory EM, Abu-Farhaneh M, Iansavitchene A, Lazo-Langner A. Venous and arterial thrombosis in ambulatory and discharged COVID-19 patients: a systematic review and meta-analysis. TH Open 2022; 6 (03) e276-e282
10 Katsoularis I, Fonseca-Rodríguez O, Farrington P. et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after COVID-19: nationwide self-controlled cases series and matched cohort study. BMJ 2022; 377: e069590
11 Knight R, Walker V, Ip S. et al; CVD-COVID-UK/COVID-IMPACT Consortium and the Longitudinal Health and Wellbeing COVID-19 National Core Study. Association of COVID-19 with major arterial and venous thrombotic diseases: a population-wide cohort study of 48 Million Adults in England and Wales. Circulation 2022; 146 (12) 892-906
12 Ortega-Paz L, Arévalos V, Fernández-Rodríguez D. et al; CV COVID-19 registry investigators. One-year cardiovascular outcomes after coronavirus disease 2019: the cardiovascular COVID-19 registry. PLoS One 2022; 17 (12) e0279333
13 de Jong CMM, Visser C, Bemelmans RHH. et al; Dutch COVID & Thrombosis Coalition investigators. Chronic thromboembolic pulmonary hypertension and clot resolution after COVID-19-associated pulmonary embolism. Eur Respir J 2023; 61 (04) 2300171
14 Bull-Otterson L, Baca S, Saydah S. et al. Post-COVID conditions among adult COVID-19 survivors aged 18–64 and ≥65 years—United States, March 2020–November 2021. MMWR Morb Mortal Wkly Rep 2022; 71 (21) 713-717
15 Fang MC, Reynolds K, Tabada GH. et al. Assessment of the risk of venous thromboembolism in nonhospitalized patients with COVID-19. JAMA Netw Open 2023; 6 (03) e232338
16 Giannis D, Goldin M, Rahman H. et al. Risk factors for post-discharge major thromboembolism and mortality in hospitalized patients with COVID-19 with cardiovascular comorbidities. Thromb Haemost 2023; 123 (11) 1089-1099
17 Roubinian NH, Vinson DR, Knudson-Fitzpatrick T. et al. Risk of posthospital venous thromboembolism in patients with COVID-19 varies by SARS-CoV-2 period and vaccination status. Blood Adv 2023; 7 (01) 141-144
18 Ranucci M, Baryshnikova E, Anguissola M, Pugliese S, Falco M, Menicanti L. The long term residual effects of COVID-associated coagulopathy. Int J Mol Sci 2023; 24 (06) 5514
19 de Jong CMM, Boon GJAM, Le YNJ, Barco S, Siegerink B, Klok FA. The post-venous thromboembolism functional status scale: from call to action to application in research, extension to COVID-19 patients, and its use in clinical practice. Semin Thromb Hemost 2023; (e-pub ahead of print)
20 Spyropoulos AC. Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients. Expert Rev Hematol 2022; 15 (07) 597-605
21 Dai MF, Xin WX, Kong S, Ding HY, Fang L. Effectiveness and safety of extended thromboprophylaxis in post-discharge patients with COVID-19: a systematic review and meta-analysis. Thromb Res 2023; 221: 105-112
22 Ramacciotti E, Barile Agati L, Calderaro D. et al; MICHELLE investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 2022; 399 (10319): 50-59
23 Wang TY, Wahed AS, Morris A. et al; ACTIV-4C Study Group. Effect of thromboprophylaxis on clinical outcomes after COVID-19 hospitalization. Ann Intern Med 2023; 176 (04) 515-523
24 Pretorius E, Venter C, Laubscher GJ. et al. Combined triple treatment of fibrin amyloid microclots and platelet pathology in individuals with long COVID/post-acute sequelae of COVID-19 (PASC) can resolve their persistent symptoms. 28 December 2021, PREPRINT (Version 1) available at Research Square.